VIPR1 and leukemia: Reduced graft-versus-leukemia effects seen in leukemic mice transplanted with allogeneic marrow and splenocytes from beige donors further supports the contribution of NK cells to the anti-cancer immune effects observed following treatment with VIP-R antagonists52.